stockportfolio.pro
Celldex Therapeutics, Inc. (CLDX)
Healthcare · Biotechnology · NasdaqCM
Celldex Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.79M | $12.74M | $9.54M | $3.57M | $7.42M | $4.65M | $2.36M | $6.88M | $7.02M | $1.54M |
| Gross profit | $5.19M | $12.04M | $8.84M | $3.47M | $7.22M | $4.55M | $2.26M | $6.58M | $6.82M | $1.34M |
| Net income | $0 | $0 | $0 | $0 | $0 | $-70.51M | $-112.33M | $-141.43M | $-157.86M | $-258.76M |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -16748.0% |
Source: Celldex Therapeutics, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Celldex Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CLDX in your portfolio →
Celldex Therapeutics, Inc. financial history by metric
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc. — frequently asked questions
What is Celldex Therapeutics, Inc.'s revenue?
Celldex Therapeutics, Inc. (CLDX) reported revenue of $1.54M for fiscal year 2025, down 78.0% from the prior year, according to its SEC filings.
Is Celldex Therapeutics, Inc. profitable?
No — CLDX reported a net loss of $-258.76M in fiscal 2025.
What is CLDX's P/E ratio?
Celldex Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Celldex Therapeutics, Inc. growing?
CLDX's revenue grew at roughly -26.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Celldex Therapeutics, Inc. have?
As of fiscal year 2025, CLDX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Celldex Therapeutics, Inc.'s gross margin?
CLDX's gross margin was 87.1% in fiscal 2025 — gross profit of $1.34M on revenue of $1.54M.
What is Celldex Therapeutics, Inc.'s market cap?
Celldex Therapeutics, Inc. (CLDX) has a market capitalization of about $2.34B, based on the latest data in our nightly-refreshed cache.
When does Celldex Therapeutics, Inc.'s fiscal year end?
CLDX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Celldex Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.